ArticleBMC infectious diseases2008
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.
Article in BMC infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00908544 (NEW ERA STUDY - HIV and Eradication), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0
Who cites it
30 citing papers in PubMed.
- Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV.PLoS computational biology · 2025Article
- Review
- Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.Current HIV/AIDS reports · 2022Review
- Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.BMC medical ethics · 2021Article
- Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.Journal of leukocyte biology · 2018Article
- A novel anti-HIV immunotherapy to cure HIV.AIDS (London, England) · 2017Article
- Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.Journal of translational medicine · 2016Review
- Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.Journal of virology · 2015Article
- Article
- Changes in HIV reservoirs during long-term antiretroviral therapy.Current opinion in HIV and AIDS · 2015Review
- Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Antimicrobial agents and chemotherapy · 2014Article
- Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation.Clinical and vaccine immunology : CVI · 2014Article
- APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.PloS one · 2013Article
- Viral latency and potential eradication of HIV-1.Expert review of anti-infective therapy · 2012Article
- Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.PLoS pathogens · 2012Article
- Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe.The Journal of infectious diseases · 2011Article
- Article
- Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.Antimicrobial agents and chemotherapy · 2010Article
- Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy.Molecular systems biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIn the setting of highly active antiretroviral therapy (HAART), plasma levels of human immunodeficiency type-1 (HIV-1) rapidly decay to below the limit of detection of standard clinical assays. However, reactivation of remaining latently infected memory CD4+ T cells is a source of continued virus production, forcing patients to remain on HAART despite clinically undetectable viral loads. Unfortunately, the latent reservoir decays slowly, with a half-life of up to 44 months, making it the major known obstacle to the eradication of HIV-1 infection. However, the mechanism underlying the long half-life of the latent reservoir is unknown. The most likely potential mechanisms are low-level viral replication and the intrinsic stability of latently infected cells.
methodsHere we use a mathematical model of T cell dynamics in the setting of HIV-1 infection to probe the decay characteristics of the latent reservoir upon initiation of HAART. We compare the behavior of this model to patient derived data in order to gain insight into the role of low-level viral replication in the setting of HAART.
resultsBy comparing the behavior of our model to patient derived data, we find that the viral dynamics observed in patients on HAART could be consistent with low-level viral replication but that this replication would not significantly affect the decay rate of the latent reservoir. Rather than low-level replication, the intrinsic stability of latently infected cells and the rate at which they are reactivated primarily determine the observed reservoir decay rate according to the predictions of our model.
conclusionThe intrinsic stability of the latent reservoir has important implications for efforts to eradicate HIV-1 infection and suggests that intensified HAART would not accelerate the decay of the latent reservoir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.